Momotaro-Gene

Executive Summary

Momotaro-Gene is a Japanese biotechnology company focused on developing next-generation cancer therapeutics using its proprietary REIC/Dkk-3 gene therapy platform. The company's core technology utilizes adenovirus vectors to deliver the REIC/Dkk-3 gene, which induces apoptosis in cancer cells and modulates the tumor microenvironment. Currently in Phase 2 clinical development, Momotaro-Gene is targeting solid tumors such as malignant glioma and liver cancer, addressing significant unmet medical needs. Despite being a private company with limited financial disclosure, its innovative approach and progress in clinical trials position it as a notable player in the oncology gene therapy space. The company's ability to advance its pipeline through Phase 2 and secure partnerships will be critical for its future success.

Upcoming Catalysts (preview)

• 2027Phase 2 data readout for malignant glioma50% success
• 2027Phase 2 data readout for liver cancer50% success
• TBDPotential strategic partnership or licensing deal30% success